Steven O’Day
0009-0005-5345-5417
Publication & Citation Trends
Publications
0 total
Abstract B036: Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab
Cited by 0
Semantic Scholar
Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
Cited by 3
Semantic Scholar
Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer
Cited by 1
Semantic Scholar
Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Cited by 14
Semantic Scholar
Monitoring botensilimab- and balstilimab-induced T-cell dynamics in refractory mismatch repair proficient metastatic colorectal cancer.
Cited by 0
Semantic Scholar
The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study.
Cited by 0
Semantic Scholar
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
Cited by 4
Semantic Scholar
Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Cited by 25
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(209)
Immunotherapy and Immune Responses
(132)
CAR-T cell therapy research
(122)
Melanoma and MAPK Pathways
(84)
Cutaneous Melanoma Detection and Management
(53)
Affiliations
Université Claude Bernard Lyon 1
Goethe University Frankfurt
University of Southern California
Cedars-Sinai Medical Center
Translational Genomics Research Institute